Citations

Clear

25 citation(s) found for "Smith, Jennifer".

Robust, flexible, and scalable tests for Hardy–Weinberg equilibrium across diverse ancestries
Kwong, Alan , Blackwell, Thomas W. , LeFaive, Jonathon , Barnes, Kathleen C. , Boerwinkle, Eric , Cade, Brian E. , Chen, Han , Conomos, Matthew P. , Eng, Celeste , Gao, Yan , Irvin, Marguerite R. , Kelly, Tanika N. , Kim, Wonji , Lubitz, Steven A. , Mathias, Rasika A. , Montasser, May E. , Musani, Solomon K., Palmer, Nicholette D, Qiao, Dandi , Reiner, Alex P. , Roden, Dan M. , Shoemaker, M. Benjamin , Smith, Jennifer A. , Smith, Nicholas L. , Lasky‐Su, Jessica , Tiwari, Hemant K., Weeks, Daniel E. , Group, TOPMed Analysis Working, Scott, Laura J. , Smith, Albert V. , Boehnke, Michael , Kang, Hyun Min , Palmer, Nicholette D. , Smith, Jennifer A , Lubitz, Steven A , Smith, Albert V , Kelly, Tanika N , Weeks, Daniel E , Palmer, Nicholette D , Mathias, Rasika A , Cade, Brian E , Lasky-Su, Jessica , Andrade, Mariza de , Barnard, John , Blangero, John , Burchard, Esteban G. , Chasman, Daniel I. , Cupples, L. Adrienne , Ellinor, Patrick T. , Guo, Xiuqing , Kooperberg, Charles , Mak, Angel C. Y. , Manichaikul, Ani , Montgomery, Courtney G. , Peloso, Gina M. , Roden, Dan M. , Weiss, Scott T. , Group, TOPMed Analysis Working, Abecasis, Gonçalo R.

Mayo Clinic

Genetics | March 15, 2021 | Volume: 218 | Issue: 1 | Pages: No page available

10.1093/genetics/iyab044 | PMID 33720349 Get It

Abstract Traditional Hardy–Weinberg equilibrium (HWE) tests (the χ2 test and the exact test) have long been used as a metric for evaluating genotype quality, as technical artifacts leading to incorrect genotype calls often can be identified as deviations from HWE. However, in data sets composed of individuals from diverse ancestries, HWE can be violated even without genotyping error, complicating the use of HWE testing to assess genotype data quality. In this manuscript, we present the Robust Unified Test for HWE (RUTH) to test for HWE while accounting for population structure and genotype uncertainty, and to evaluate the impact of population heterogeneity and genotype uncertainty on the standard HWE tests and alternative methods using simulated and real sequence data sets. Our results demonstrate that ignoring population structure or genotype uncertainty in HWE tests can inflate false-positive rates by many orders of magnitude. Our evaluations demonstrate different tradeoffs between false positives and statistical power across the methods, with RUTH consistently among the best across all evaluations. RUTH is implemented as a practical and scalable software tool to rapidly perform HWE tests across millions of markers and hundreds of thousands of individuals while supporting standard VCF/BCF formats. RUTH is publicly available at https://www.github.com/statgen/ruth.
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Gerds, Aaron T. , Savona, Michael R. , Scott, Bart L. , Egyed, Miklós , Harrison, Claire , Yacoub, Abdulraheem , Vannucchi, Alessandro M. , Mead, Adam J. , O’Sullivan, Jennifer , García‐Gutiérrez, Valentín , Rampal, Raajit K. , Miller, Carole B., Palmer, Jeanne , Buckley, Sarah , Mould, Diane R. , Ito, Kaori , Tyavanagimatt, Shanthakumar , Roman‐Torres, Karisse, Devineni, Sri, Craig, Adam R., Vannucchi, Alessandro M , Gerds, Aaron T , Savona, Michael R , Mead, Adam J , Talpaz, Moshe , Kiladjian, Jean‐Jacques , Bose, Prithviraj , Oh, Stephen T. , Smith, Jennifer A. , Mascarenhas, John

Mayo Clinic

Blood Advances | December 3, 2020 | Volume: 4 | Issue: 22 | Pages: 5825-5835

10.1182/bloodadvances.2020003314 | PMID 33232476 Get It

Abstract PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduction in the 7-component total symptom score (TSS) through week 24. Of 161 patients, 73% were intolerant of and 76% had become resistant to ruxolitinib; 50% met criteria for both. Severe thrombocytopenia (platelet count <50 × 103/μL) was present in 44%. SVR rates were highest with 200 mg twice per day (100 mg once per day, 0%; 100 mg twice per day, 1.8%; 200 mg twice per day, 9.3%), particularly among patients with baseline platelet counts <50 × 103/μL (17%; 4 of 24). Although TSS response rate was similar across doses (100 mg once per day, 7.7%; 100 mg twice per day, 7.3%; 200 mg twice per day, 7.4%), median percent reduction in TSS suggested a dose-response relationship (–3%, −16%, and −27%, respectively). Pharmacokinetic and pharmacodynamic modeling based on all available data showed greatest SVR and TSS reduction at 200 mg twice per day compared with lower doses. Common adverse events were gastrointestinal events, thrombocytopenia, and anemia. There was no excess of grade ≥3 hemorrhagic or cardiac events at 200 mg twice per day. Pacritinib 200 mg twice per day demonstrated clinical activity and an acceptable safety profile and was selected as the recommended dose for a pivotal phase 3 study in patients with myelofibrosis and severe thrombocytopenia. This trial was registered at www.clinicaltrials.gov as #NCT03165734.
Postoperative Recovery Comparisons of Arthroscopic Bankart to Open Latarjet for the Treatment of Anterior Glenohumeral Instability
Smith, Jennifer , Higgins, Laurence D. , Woodmass, Jarret Murray , Wagner, Eric R. , Warner, Jon J.P.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 29, 2019 | Volume: 7 | Issue: 7_suppl5 | Pages: No page available

10.1177/2325967119s00272 Get It

Objectives: Recurrent anterior glenohumeral instability is a disabling pathology that can be successfully treated by arthroscopic Bankart repair or an open Latarjet procedure. Long-term outcomes have shown lower rates of apprehension, recurrent dislocation and operative revision following Latarjet when compared to Bankart repair. However, there is a paucity of studies comparing the short-term post-operative recovery of arthroscopic Bankart versus open Latarjet. The purpose of this study is to evaluate the post-operative recovery following Bankart and the open Latarjet procedure. Methods: The surgical outcomes system (SOS) database (Arthrex Inc., Naples, FL) was used to compare the post-operative recovery outcomes after either a primary or revision arthroscopic Bankart and an open Latarjet procedure. Patients were included who had a minimum of 1 year follow-up. Preoperative and postoperative (2 weeks, 6 weeks, 3 months, 6 months, 1 year and 2 year) time points were evaluated. Outcomes measures included Visual Analog Pain Scale (VAS), American Shoulder and Elbow Surgeons (ASES) Shoulder Function Score, ASES Shoulder Index Score, and SANE Score. Overall, 787 patients underwent primary Bankart (518 male, 240 female, 4 not recorded), 36 underwent revision Bankart (24 male, 10 female, 2 not recorded) and 75 underwent an open Latarjet procedure (59 male, 12 female, 4 not recorded). The mean age for primary Bankart, revision Bankart, and open Latarjet was 40.8, 38.6 and 32.8 respectively. Additionally, the average BMI for primary Bankart, revision Bankart, and open Latarjet was 27.2, 28.13, and 25.6, respectively. Results: The postoperative recovery curves are displayed in Figure 1. When compared to primary Bankart, open Latarjet demonstrated significantly lower VAS scores at six weeks (p=0.0272) and at three months (p=0.0094). Medium term outcomes for ASES Shoulder Index Score, ASES Shoulder Function Score, and SANE Score, at 1- and 2-years showed no difference between primary Bankart and Latarjet. For the revision Bankart and open Latarjet procedures, the open Latarjet cohort demonstrated significantly higher ASES Shoulder Index Scores at the 3-months (p= 0.0017), 1-year (p= 0.0021), and 2-years (p= 0.0006) timepoints. Open Latarjet patients also had significantly higher ASES Shoulder Function Scores than revision Bankart at 3-months (p= 0.0162), 1-year (p= 0.0083), and 2-years (p= 0.0013). Revision Bankart repair resulted in significantly higher VAS scores than open Latarjet at 2-weeks (p= 0.0025), 6-weeks (p=0.0114), 3-months (p= 0.0024), 1-year (p= 0.0039), and 2-years (p= 0.0007). Conclusion: When compared to Bankart repair, open Latarjet provides improved pain and functional outcomes during the early recovery phase, 2-weeks, 6-weeks, 3-months, and 6-months, with equivalent medium-term outcomes at 1-2-years. Furthermore, when compared to revision Bankart reconstruction, open Latarjet provides improved ASES Shoulder Index Scores, ASES Shoulder Function Scores and VAS Scores at nearly all timepoints. In the treatment of recurrent anterior glenohumeral instability, open Latarjet is reasonable option in the primary setting and should be favored over Bankart repair for revision cases with improved pain relief and functional scores.
Quantitative phenotype analysis to identify, validate and compare rat disease models
Zhao, Yiqing , Smith, Jennifer R. , Wang, Shur‐Jen , Dwinell, Melinda R. , Shimoyama, Mary

Mayo Clinic

Database | March 5, 2019 | Volume: 2019 | Issue: No issue available | Pages: No page available

10.1093/database/baz037 | PMID 30938777 Get It

Longitudinal analysis of epigenome-wide DNA methylation reveals novel smoking-related loci in African Americans
Liu, Jiaxuan , Zhao, Wei , Ammous, Farah , Mosley, Thomas H. , Zhou, Xiang , Smith, Jennifer A. , Zhao, Wei , Turner, Stephen T. , Zhou, Xiang , Smith, Jennifer A , Zhao, Wei

Mayo Clinic

Epigenetics | February 15, 2019 | Volume: 14 | Issue: 2 | Pages: 171-184

10.1080/15592294.2019.1581589 | PMID 30764717 Get It

Exome Chip Analysis Identifies Low-Frequency and Rare Variants in MRPL38 for White Matter Hyperintensities on Brain Magnetic Resonance Imaging
Jian, Xueqiu , Satizábal, Claudia L. , Smith, Albert V. , Wittfeld, Katharina , Bis, Joshua C. , Smith, Jennifer A. , Hofer, Edith , Mishra, Aniket , Adams, Hieab H.H. , Li, Shuo , Teumer, Alexander , Zhao, Wei , Saba, Yasaman , Yanek, Lisa R. , Chauhan, Ganesh , Buchem, Mark A. van , Royle, Natalie A., Niessen, Wiro J. , Windham, B. Gwen , DeStefano, Anita L. , Habes, Mohamad , Heckbert, Susan R. , Palmer, Nicholette D., Lewis, Cora E. , Eiríksdóttir, Guðný , Maillard, Pauline , Mathias, Rasika A. , Divers, Jasmin, Beiser, Alexa S., Langner, Sönke , Rice, Kenneth , Bastin, Mark E. , Starr, John M. , Sidney, Stephen , Risacher, Shannon L. , Uitterlinden, André G. , Guðnason, Vilmundur , Rotter, Jerome I. , Schreiner, Pamela J. , Boerwinkle, Eric , Duijn, Cornelia M. van , Sarnowski, Bettina von , Gottesman, Rebecca F., Levy, Daniel , Sigurðsson, Sigurður , Vernooij, Meike W. , Schmidt, Reinhold, Wardlaw, Joanna M. , Mosley, Thomas H. , DeCarli, Charles , Bowden, Donald W. , Becker, Diane M. , Deary, Ian J. , Schmidt, Helena , Kardia, Sharon L. R., Debette, Stéphanie , Longstreth, W.T. , Seshadri, Sudha , Launer, Lenore J. , Fornage, Myriam , Group, for the neuroCHARGE Working, Dichgans, Martin , Rice, Kenneth , Palmer, Nicholette D. , DeCarli, Charles , Turner, Stephen T. , Dichgans, Martin , Wardlaw, Joanna Marguerite , Smith, Jennifer A , Adams, Hieab H H , Satizabal, Claudia L , Seshadri, Sudha , Bastin, Mark E , Teumer, Alexander , van Duijn, Cornelia M , Debette, Stephanie , Smith, Albert V , Palmer, Nicholette D , Rotter, Jerome I , Mathias, Rasika A , Rice, Ken , Levy, Daniel , Hsu, Fang‐Chi , Nho, Kwangsik T. , Hagenaars, Saskia P. , Nyquist, Paul , Freedman, Barry I. , Cushman, Mary , Bryan, Robert Nick , Homuth, Georg , Hernández, Maria del Carmen Valdés , Divers, Jasmin , Yang, Qiong , Maldjian, Joseph A. , Nauck, Matthias A. , Mazoyer, Bernard , Psaty, Bruce M. , Saykin, Andrew J. , Ikram, M. Arfan , Grabe, Hans Jörgen , Group, for the neuroCHARGE Working, Maillard, Pauline

Mayo Clinic

Stroke | July 12, 2018 | Volume: 49 | Issue: 8 | Pages: 1812-1819

10.1161/strokeaha.118.020689 | PMID 30002152 Get It

Background and Purpose— White matter hyperintensities (WMH) on brain magnetic resonance imaging are typical signs of cerebral small vessel disease and may indicate various preclinical, age-related neurological disorders, such as stroke. Though WMH are highly heritable, known common variants explain a small proportion of the WMH variance. The contribution of low-frequency/rare coding variants to WMH burden has not been explored. Methods— In the discovery sample we recruited 20 719 stroke/dementia-free adults from 13 population-based cohort studies within the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, among which 17 790 were of European ancestry and 2929 of African ancestry. We genotyped these participants at ≈250 000 mostly exonic variants with Illumina HumanExome BeadChip arrays. We performed ethnicity-specific linear regression on rank-normalized WMH in each study separately, which were then combined in meta-analyses to test for association with single variants and genes aggregating the effects of putatively functional low-frequency/rare variants. We then sought replication of the top findings in 1192 adults (European ancestry) with whole exome/genome sequencing data from 2 independent studies. Results— At 17q25, we confirmed the association of multiple common variants in TRIM65 , FBF1 , and ACOX1 ( P <6×10 −7 ). We also identified a novel association with 2 low-frequency nonsynonymous variants in MRPL38 (lead, rs34136221; P EA =4.5×10 −8 ) partially independent of known common signal ( P EA(conditional) =1.4×10 −3 ). We further identified a locus at 2q33 containing common variants in NBEAL1 , CARF , and WDR12 (lead, rs2351524; P all =1.9×10 −10 ). Although our novel findings were not replicated because of limited power and possible differences in study design, meta-analysis of the discovery and replication samples yielded stronger association for the 2 low-frequency MRPL38 variants ( P rs34136221 =2.8×10 −8 ). Conclusions— Both common and low-frequency/rare functional variants influence WMH. Larger replication and experimental follow-up are essential to confirm our findings and uncover the biological causal mechanisms of age-related WMH.
Functional Invalidation of Putative Sudden Infant Death Syndrome–Associated Variants in the KCNH2 -Encoded Kv11.1 Channel
Tester, David J. , Hall, Allison R., Burgess, Don E. , Hsu, Chun‐Chun , Elayi, Samy Claude, Anderson, Corey L. , January, Craig T., Luo, Jonathan Z. , Hartzel, Dustin N. , Murray, Michael F. , Ackerman, Michael J. , Delisle, Brian P. , Smith, Jennifer L. , Mirshahi, Uyenlinh L. , Mirshahi, Tooraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 11, 2018 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/circep.117.005859 | PMID 29752375 Get It

Background: Heterologous functional validation studies of putative long-QT syndrome subtype 2–associated variants clarify their pathological potential and identify disease mechanism(s) for most variants studied. The purpose of this study is to clarify the pathological potential for rare nonsynonymous KCNH2 variants seemingly associated with sudden infant death syndrome. Methods: Genetic testing of 292 sudden infant death syndrome cases identified 9 KCNH2 variants: E90K, R181Q, A190T, G294V, R791W, P967L, R1005W, R1047L, and Q1068R. Previous studies show R181Q-, P967L-, and R1047L-Kv11.1 channels function similar to wild-type Kv11.1 channels, whereas Q1068R-Kv11.1 channels accelerate inactivation gating. We studied the biochemical and biophysical properties for E90K-, G294V-, R791W-, and R1005W-Kv11.1 channels expressed in human embryonic kidney 293 cells; examined the electronic health records of patients who were genotype positive for the sudden infant death syndrome–linked KCNH2 variants; and simulated their functional impact using computational models of the human ventricular action potential. RESULTS: Western blot and voltage-clamping analyses of cells expressing E90K-, G294V-, R791W-, and R1005W-Kv11.1 channels demonstrated these variants express and generate peak Kv11.1 current levels similar to cells expressing wild-type-Kv11.1 channels, but R791W- and R1005W-Kv11.1 channels accelerated deactivation and activation gating, respectively. Electronic health records of patients with the sudden infant death syndrome–linked KCNH2 variants showed that the patients had median heart rate–corrected QT intervals <480 ms and none had been diagnosed with long-QT syndrome or experienced cardiac arrest. Simulating the impact of dysfunctional gating variants predicted that they have little impact on ventricular action potential duration. Conclusions: We conclude that these rare Kv11.1 missense variants are not long-QT syndrome subtype 2–causative variants and therefore do not represent the pathogenic substrate for sudden infant death syndrome in the variant-positive infants.
Association of urinary citrate excretion, pH, and net gastrointestinal alkali absorption with diet, diuretic use, and blood glucose concentration
Perinpam, Majuran, Smith, Jennifer A. , Kardia, Sharon L. R., Turner, Stephen T. , Smith, Jennifer A , Ware, Erin Bakshis , Lieske, John C.

Mayo Clinic

Physiological Reports | October 17, 2017 | Volume: 5 | Issue: 19 | Pages: e13411

10.14814/phy2.13411 | PMID 29038354 Get It

Correction: The complex genetics of gait speed: genome-wide meta-analysis approach
Ben-Avraham, Dan, Karasik, David , Verghese, Joe , Lunetta, Kathryn L. , Eicher, John D., Vered, Rotem, Deelen, Joris , Arnold, Alice M. , Buchman, Aron S. , Faul, Jessica D. , Nethander, Maria , Fornage, Myriam , Adams, Hieab H.H. , Matteini, Amy M., Callisaya, Michele L. , Smith, Albert V. , Yu, Lei, Jager, Philip L. De , Evans, Denis A., Guðnason, Vilmundur , Hofman, Albert , Pattie, Alison, Knopman, Davis S., Parimi, Neeta, Bandinelli, Stefania , Beekman, Marian , Gutman, Danielle , Sharvit, Lital , Mooijaart, Simon P. , Liewald, David C. , Houwing‐Duistermaat, Jeanine J. , Ohlsson, Claes , Moed, Matthijs, Hernandez, Dena, Thomson, Russell , Tranah, Gregory J. , Weir, David R. , Zhao, Wei , Starr, John M. , Johnson, Andrew D. , Bennett, David A. , Cummings, Steven R. , Deary, Ian J. , Harris, Tamara B., Kardia, Sharon L. R., Mosley, Thomas H. , Srikanth, Velandai , Windham, B. Gwen , Davies, Gail , Evans, Daniel S. , Ferrucci, Luigi , Atzmon, Gil , Bennett, David A. , Turner, Stephen T. , Smith, Jennifer A. , Tanaka, Toshiko , Corley, Janie , Launer, Lenore J. , Verlinden, Vincentius J.A. , Mellström, Dan , Geest, Jos N. van der , Karlsson, Magnus K , McWhirter, Rebekah , Liu, Ching‐Ti , Uitterlinden, André G. , Ikram, M. Arfan , Newman, Anne B. , Walston, Jeremy D , Slagboom, P. Eline , Kiel, Douglas P. , Murabito, Joanne M. , Adams, Hieab H H , Smith, Albert V , Ferrucci, Luigi , Ohlsson, Claes , Srikanth, Velandai K

Mayo Clinic

Aging | July 7, 2017 | Volume: 9 | Issue: 7 | Pages: 1844-1846

10.18632/aging.101260 | PMID 28696945 Get It

The complex genetics of gait speed: genome-wide meta-analysis approach
Ben-Avraham, Dan, Karasik, David , Verghese, Joe , Lunetta, Kathryn L. , Smith, Jennifer A. , Eicher, John D., Vered, Rotem, Deelen, Joris , Arnold, Alice M. , Buchman, Aron S. , Faul, Jessica D. , Nethander, Maria , Fornage, Myriam , Adams, Hieab H.H. , Matteini, Amy M., Callisaya, Michele L. , Smith, Albert V. , Yu, Lei, Jager, Philip L. De , Evans, Denis A., Guðnason, Vilmundur , Hofman, Albert , Pattie, Alison, Knopman, Davis S., Parimi, Neeta, Bandinelli, Stefania , Beekman, Marian , Gutman, Danielle , Sharvit, Lital , Mooijaart, Simon P. , Liewald, David C. , Houwing‐Duistermaat, Jeanine J. , Ohlsson, Claes , Moed, Matthijs, Hernández, Dena , McWhirter, Rebekah , Thomson, Russell , Tranah, Gregory J. , Uitterlinden, André G. , Weir, David R. , Zhao, Wei , Starr, John M. , Johnson, Andrew D. , Bennett, David A. , Cummings, Steven R. , Deary, Ian J. , Harris, Tamara B., Kardia, Sharon L. R., Mosley, Thomas H. , Srikanth, Velandai , Windham, B. Gwen , Davies, Gail , Evans, Daniel S. , Ferrucci, Luigi , Atzmon, Gil , Bennett, David A. , Turner, Stephen T. , Tanaka, Toshiko , Corley, Janie , Launer, Lenore J. , Verlinden, Vincentius J.A. , Mellström, Dan , Geest, Jos N. van der , Karlsson, Magnus K , Liu, Ching‐Ti , Ikram, M. Arfan , Newman, Anne B. , Walston, Jeremy D , Slagboom, P. Eline , Kiel, Douglas P. , Murabito, Joanne M. , Smith, Jennifer A , Adams, Hieab H H , Smith, Albert V , Ferrucci, Luigi , Ohlsson, Claes , Srikanth, Velandai K

Mayo Clinic

Aging | December 30, 2016 | Volume: 9 | Issue: 1 | Pages: 209-246

10.18632/aging.101151 | PMID 28077804 Get It